touchCONGRESS HR+/HER2- Advanced breast cancer: what are the latest developments in CDK4/6 inhibition from the ASCO Meeting 2019?

In this interview, Véronique Diéras answers the following questions:

• Overall survival data from the MONALEESA-7 trial were presented at ASCO 2019. How do you think these data will affect the use of CDK4/6 inhibitors, both globally and in your region?
• Data have been presented for CDK4/6 inhibitors in both the first- and second-line settings. How do you think this evidence will alter how CDK4/6 inhibitors are integrated into clinical practice?
• Long-term safety data for a CDK4/6 inhibitor in patients with advanced breast cancer were presented. What is the role of the multidisciplinary team in your institution in maintaining treatment benefit?
• Data for possible prognostic biomarkers for CDK4/6 inhibitors were shared. To what extent could this information help guide therapy in your clinical practice?
• Targeting resistance using CDK4/6 inhibitors in combination with other therapies has been studied. How do you think these findings could help optimize treatment, both globally and in your region?
• Did any CDK4/6 inhibitor data stand out for you at ASCO 2019, and why? What are the implications for patient management in your region?

Dr Véronique Diéras, MD, is senior medical oncologist and head of the Breast Cancer Group in the Department of Medical Oncology at the Centre Eugène Marquis in Rennes, France and former Head of Clinical Research, Department of Medical Oncology at the Institut Curie, Paris, France.

Dr Diéras received her medical training at the University of Nantes, France, and completed residencies and further specialty training at the Hospital of Rennes and at the Institut Curie. She also earned a master’s degree in human biology at the University of Paris Saint-Antoine and in oncopharmacology at the University of Paris Saint-Louis-Lariboisière.

Her main focus is breast cancer treatment and research and early drug development. Dr Diéras is involved in early clinical trials, breast cancer trials, and a translational research programme focusing primarily on predictive factors of response to treatment and is principal investigator in several national and international studies of breast and other cancers in adjuvant treatment and metastatic disease.

Dr Diéras is a member of several societies including the European Society of Medical Oncology (Scientific Committee), the American Society of Clinical Oncology, the European Organisation for Research and Treatment of Cancer [EORTC] (and was previously a member of the EORTC’s New Drug Development Programme, Drug Study Group in Oncology, and Breast Group, Protocol Review Committee), French Drug Agency, Institut National du Cancer and UNICANCER (Breast Board, Early Clinical trials, Personalized Medicine, and former chair of the Early Clinical Trials Group). She is a participant in the European School of Oncology. Dr. Diéras serves on the editorial board of La Lettre du Cancérologue and as a reviewer for various oncology journals.

She is author or co-author of more than 190 publications in such journals as the Journal of Clinical Oncology, New England Journal of Medicine, Annals of Oncology, The Lancet Oncology, Cancer Chemotherapy and Pharmacology, the British Journal of Cancer and the International Journal of Cancer.

Dr Véronique Diéras discloses: Consultant for AbbVie, Astellas, AstraZeneca, Daiichi Sankyo, Eisai, Lilly, Merck Sharp & Dohme, Nektar, Novartis, Odonate, Pfizer, Roche/Genentech, Seattle Genetics and Tesaro.  Speaker honoraria from AstraZeneca, Eisai, Lilly, Novartis, Pfizer and Roche; travel expenses from AstraZeneca, Lilly, Novartis, Pfizer and Roche.

In this interview, Sherko Kümmel answers the following questions:

• Overall survival data from the MONALEESA-7 trial were presented at ASCO 2019. How do you think these data will affect the use of CDK4/6 inhibitors, both globally and in your region?
• Data have been presented for CDK4/6 inhibitors in both the first- and second-line settings. How do you think this evidence will alter how CDK4/6 inhibitors are integrated into clinical practice?
• Long-term safety data for a CDK4/6 inhibitor in patients with advanced breast cancer were presented. What is the role of the multidisciplinary team in your institution in maintaining treatment benefit?
• Data for possible prognostic biomarkers for CDK4/6 inhibitors were shared. To what extent could this information help guide therapy in your clinical practice?
• Targeting resistance using CDK4/6 inhibitors in combination with other therapies has been studied. How do you think these findings could help optimize treatment, both globally and in your region?
• Did any CDK4/6 inhibitor data stand out for you at ASCO 2019, and why? What are the implications for patient management in your region?

Prof. Sherko Kümmel is Clinical Director and Chairman of the Interdisciplinary Breast Unit and Lead of the Breast Cancer Research Programme at Kliniken Essen-Mitte, Germany. He is an Executive Board Member of the AGO (Arbeitsgemeinschaft Gynäkologische Onkologie). In 2018, he became Extraordinary Professor of the Medical School, University Hospital Charité at Humboldt University Berlin, Germany.

Prof. Kümmel graduated from the Medical School at Humboldt University Berlin, Germany in 1997. He completed his Medical Doctorate in 2000, focussing on ‘MRI of focal liver lesions with new liver specific contrast media Gd-EOB-DTPA’ at the Clinical Dept. of Radiology, Charité – University Medicine Berlin in Germany. His PhD research investigating ‘Adjuvant dose dense Chemotherapy at patients with high risk lymph node positive breast cancer’ was completed in 2008 and carried out at the Dept. of Gynaecology and Obstetrics, University Hospital Essen, Germany.

Prof. Kümmel has the following Board Certifications: Gynaecology and Obstetrics (Germany 2004); Specialization in Gynaecological Oncology (Germany 2007); Specialization in medical tumour therapy (Germany 2007); Specialized Breast Surgeon (Germany 2016).

Prof. Kümmel has a substantial track record of successful completion of national/international studies as the chief investigator (23 Phase I–III clinical studies) or principal investigator (78 Phase Ib–III clinical studies) and has served on the steering/protocol board of 37 Phase I–III clinical studies and as sub investigator for a further 27 Phase II–III studies.

Prof. Kümmel has over 200 publications in peer-reviewed journals and 25 as first author. He has also published 194 congress abstracts/proceedings, 51 books/book chapters and has been invited to give 754 oral presentations or lectures.

Prof. Kümmel has also served as speaker of the AGIMed Commission for Integrative Medicine of the AGO and as a Member of the Organ Commission Mamma of the AGO. Additional roles include Scientific Director of the West German Study Group (WSG), a member of the Scientific Committee of the North-Eastern German Society of Gynecological Oncology (NOGGO) – Breast Group, Independent Data Monitoring Committee’s (IDMC) Steering Boards (national and international), and a member of the Scientific Committee of National Symposia in Breast Cancer and Surgical Oncology.

Prof. Sherko Kümmel discloses:  Consulting or advisory roles with Amgen, AstraZeneca, Celgene, Daiichi Sankyo, Genomic Health, Merck Sharp & Dohme Oncology, Novartis, Pfizer, pfm medical, Puma Biotechnology, Roche/Genentech, and SOMATEX.  Speakers’ Bureau, Travel, Accommodation, Expenses for Daiichi Sankyo and Roche.

In this interview, Patrick Neven answers the following questions:

• Overall survival data from the MONALEESA-7 trial were presented at ASCO 2019. How do you think these data will affect the use of CDK4/6 inhibitors, both globally and in your region?
• Data have been presented for CDK4/6 inhibitors in both the first- and second-line settings. How do you think this evidence will alter how CDK4/6 inhibitors are integrated into clinical practice?
• Long-term safety data for a CDK4/6 inhibitor in patients with advanced breast cancer were presented. What is the role of the multidisciplinary team in your institution in maintaining treatment benefit?
• Data for possible prognostic biomarkers for CDK4/6 inhibitors were shared. To what extent could this information help guide therapy in your clinical practice?
• Targeting resistance using CDK4/6 inhibitors in combination with other therapies has been studied. How do you think these findings could help optimize treatment, both globally and in your region?
• Did any CDK4/6 inhibitor data stand out for you at ASCO 2019, and why? What are the implications for patient management in your region?

Prof. Dr Patrick Neven, MD, PhD, is an oncologist at the Universitair Ziekenhuis Leuven (UZ Leuven) Breast Centre, a research-based university hospital in Leuven, Belgium. Also offering gynaecologic oncology care, Prof. Dr. Neven has worked at the hospital for 18 years. Prior to this, he was an oncologist at the multidisciplinary-based Kliniek Sint-Jan in Brussels for 15 years.

Prof. Dr. Neven completed his medical degree in 1986 at the Katholieke Universiteit, Leuven, where he later completed his PhD in 1998. He is an experienced researcher, having completed 200 studies within female urogenital diseases and pregnancy complications, including Phase III trials.

Committed to advancing oncology healthcare, Prof. Dr. Neven currently has 10 ongoing studies. Notable research that he has been involved in includes the use of third-generation aromatase inhibitors for the prevention of locoregional and contralateral breast cancer in postmenopausal women, as well as the progression-free survival efficacy of CDK4/6 inhibitors in young women with endocrine-resistant breast cancer.

Prof. Dr Patrick Neven discloses:  Travel expenses from Pfizer. Honoraria received by my institution from Eli Lilly, Novartis, Pfizer and Roche for consultancy and advisory boards. Research funding received by my institution from Kom op tegen Kanker.

In this interview, Joohyuk Sohn answers the following questions:

• Overall survival data from the MONALEESA-7 trial were presented at ASCO 2019. How do you think these data will affect the use of CDK4/6 inhibitors, both globally and in your region?
• Data have been presented for CDK4/6 inhibitors in both the first- and second-line settings. How do you think this evidence will alter how CDK4/6 inhibitors are integrated into clinical practice?
• Long-term safety data for a CDK4/6 inhibitor in patients with advanced breast cancer were presented. What is the role of the multidisciplinary team in your institution in maintaining treatment benefit?
• Data for possible prognostic biomarkers for CDK4/6 inhibitors were shared. To what extent could this information help guide therapy in your clinical practice?
• Targeting resistance using CDK4/6 inhibitors in combination with other therapies has been studied. How do you think these findings could help optimize treatment, both globally and in your region?
• Did any CDK4/6 inhibitor data stand out for you at ASCO 2019, and why? What are the implications for patient management in your region?

Prof. Joohyuk Sohn is Professor and current Chief of the Division of Medical Oncology at the Yonsei Cancer Center, Yonsei University College of Medicine, Severance Hospital, Yonsei University Health System, Seoul, Korea.

Prof. Sohn graduated in 1993 from the Yonsei University College of Medicine, and also gained his MSc and PhD there in 2001 and 2008, respectively. He worked as a Military Doctor from 1994–1997 at Wondang, Kyunggi Do, Korea. His Residency in Internal Medicine from 1998 to 2002 was followed by a 2-year Clinical Fellowship in Medical Oncology at the Division of Haemato-Oncology, Department of Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Korea. He progressed to Instructor (2004), Assistant Professor (2006) and from 2011–2013 was a Visiting Associate Professor in Breast Medical Oncology and Systems Biology at the MD Anderson Cancer Center, Houston, Texas, USA. Joohyuk Sohn became Professor in 2015 and took up his current position at Yonsei University College of Medicine in 2017.

Prof. Sohn has membership of the Korean Association of Internal Medicine, the Korean Cancer Study Group and the American Society of Clinical Oncology (2002) and in 2004 attained a Merit Award at the ASCO Annual Meeting. In addition, since 2009, he has been a member of the American Association for Cancer Research.

Prof. Sohn has been involved in clinical research since 2007, contributing to over 100 clinical studies in the field of breast medical oncology. He is co-author of over 50 publications and was first author or corresponding author to 11 of these.

Prof. Joohyuk Sohn has no financial interests/relationships or affiliations to disclose in relation to this activity.

In this interview Joyce A. O’Shaughnessy answers the following questions:

• Overall survival data from the MONALEESA-7 trial were presented at ASCO 2019. How do you think these data will affect the use of CDK4/6 inhibitors, both globally and in your region?
• Data have been presented for CDK4/6 inhibitors in both the first- and second-line settings. How do you think this evidence will alter how CDK4/6 inhibitors are integrated into clinical practice?
• Long-term safety data for a CDK4/6 inhibitor in patients with advanced breast cancer were presented. What is the role of the multidisciplinary team in your institution in maintaining treatment benefit?
• Data for possible prognostic biomarkers for CDK4/6 inhibitors were shared. To what extent could this information help guide therapy in your clinical practice?
• Targeting resistance using CDK4/6 inhibitors in combination with other therapies has been studied. How do you think these findings could help optimize treatment, both globally and in your region?
• Did any CDK4/6 inhibitor data stand out for you at ASCO 2019, and why? What are the implications for patient management in your region?

Dr Joyce A. O’Shaughnessy, M.D. specializes in medical oncology with board certification in both internal medicine as well as medical oncology. She is a Diplomate of the American Board of Internal Medicine with subspecialty certification in medical oncology. Dr. O’Shaughnessy focuses her practice and clinical research on breast cancer treatment. She is Director of Breast Cancer Research at the Baylor-Sammons Cancer Center and Chair of Breast Cancer Research for The US Oncology Network.

Dr O’Shaughnessy received her M.D. from Yale University Medical School. Her internship and residency in internal medicine were completed at Massachusetts General Hospital in 1985. She concluded a fellowship in medical oncology at the National Cancer Institute in 1987 and was a Senior Investigator there until 1995.

Dr O’Shaughnessy’s memberships include the American Association for Cancer Research, the American Society of Clinical Oncology, the American College of Physicians and Women in Cancer Research. She is Associate Editor of Clinical Breast Cancer and Founder of the School of Breast Oncology.

Dr O’Shaughnessy has received the following Honours and Awards: Giants of Cancer Care: Community Outreach/Education Award; Baylor University Medical Center: Staff Chief’s award; Holy Cross College: Sanctae Crucis Award (Distinguished Alumni Award); Public Health Service Special Service: Development of the Consensus Statement on Cancer Drug Approval Endpoints Award; and the Yale Medical School: Francis Parker Award (Faculty Choice for Most Promising Clinician).

Her research interests include genotype-phenotype correlations for high risk breast cancers and also immunotherapy for triple negative breast cancer.

Dr Joyce A. O’Shaughnessy discloses:  Honoraria as a speaker or consultant from AbbVie Inc., Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health, GRAIL, Immunomedics, Heron Therapeutics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly,
Merck, Myriad, Novartis, Odonate Therapeutics, Pfizer, Puma Biotechnology, Roche, Seattle Genetics and Syndax Pharmaceuticals.

In this interview, Michelino De Laurentiis answers the following questions:

• Overall survival data from the MONALEESA-7 trial were presented at ASCO 2019. How do you think these data will affect the use of CDK4/6 inhibitors, both globally and in your region?
• Data have been presented for CDK4/6 inhibitors in both the first- and second-line settings. How do you think this evidence will alter how CDK4/6 inhibitors are integrated into clinical practice?
• Long-term safety data for a CDK4/6 inhibitor in patients with advanced breast cancer were presented. What is the role of the multidisciplinary team in your institution in maintaining treatment benefit?
• Data for possible prognostic biomarkers for CDK4/6 inhibitors were shared. To what extent could this information help guide therapy in your clinical practice?
• Targeting resistance using CDK4/6 inhibitors in combination with other therapies has been studied. How do you think these findings could help optimize treatment, both globally and in your region?
• Did any CDK4/6 inhibitor data stand out for you at ASCO 2019, and why? What are the implications for patient management in your region?

Prof, Michelino De Laurentiis took his Medical Degree in 1989 at the University ‘Federico II’ in Naples, Italy and he was awarded a clinical fellowship in medical oncology at the same University. Between 1992 and 1994, he worked as a research fellow at the Division of Medical Oncology, The University of Texas Health Science Center, San Antonio, TX, USA, focusing on the development of prognostic models for breast cancer. In 2000, he obtained a PhD degree for clinical research in oncology and was also appointed as attending physician at the Division of Medical Oncology of the ‘Federico II’ University Hospital. Between 2002 and 2010, he held the position of Assistant Professor of Medical Oncology in the Department of Endocrinology and Molecular and Clinical Oncology, University ‘Federico II’, where he took responsibility for breast cancer systemic therapy and clinical and translational breast cancer research. In 2010, he moved to the National Cancer Institute ‘Fondazione Pascale, where he became Director of Breast Oncology. In 2015, he was appointed as Affiliate Professor at Temple University, Philadelphia, PA, USA.

Currently, Prof. De Laurentiis heads the Department of Breast and Thoracic Oncology and is the Coordinator of the Comprehensive Cancer Center at the National Cancer Institute ‘Fondazione Pascale’. He is a member of the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO) and the Italian Society of Medical Oncology (AIOM). He is a founding member of the main Italian group for clinical research in breast cancer (Gruppo Italiano Mammella; GIM). He also sits as a member of the Scientific Committee and the Translational Research Committee of the GIM and he is directly responsible for the coordination of clinical breast cancer trials and translational studies.

Prof. De Laurentiis holds steering committee positions in several international trials and in some of these he acts as principal investigator. He serves as a reviewer for various journals and he has authored about 140 papers in peer-reviewed journals. His main research interests are breast cancer treatment and prognostic and predictive factors.

Prof. Michelino De Laurentiis discloses:  Speaker honoraria from Amgen, Novartis and Pierre Fabre.  Consulting or Advisory Role for Eli Lilly, Myriad, Novartis and Roche.  Travel expenses from Novartis.